{"id":"salbutamol","rwe":[],"tags":[{"label":"beta2-Adrenergic Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-2 adrenergic receptor","category":"target"},{"label":"ADRB2","category":"gene"},{"label":"ADRB1","category":"gene"},{"label":"R03AC02","category":"atc"},{"label":"Respiratory (Inhalation)","category":"route"},{"label":"Oral","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Active","category":"status"},{"label":"Acute exacerbation of asthma","category":"indication"},{"label":"Bronchospasm","category":"indication"},{"label":"Bronchospasm Prevention","category":"indication"},{"label":"Chronic Obstructive Pulmonary Disease with Bronchospasms","category":"indication"},{"label":"Exercise-Induced Bronchospasm Prevention","category":"indication"},{"label":"Schering","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic beta-2 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic beta-Agonists","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Tocolytic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":10950.875,"date":"","count":9196,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 9,196 times (LLR=10951)"},{"llr":7563.774,"date":"","count":6836,"signal":"Wheezing","source":"DrugCentral FAERS","actionTaken":"Reported 6,836 times (LLR=7564)"},{"llr":5324.559,"date":"","count":17246,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 17,246 times (LLR=5325)"},{"llr":3973.12,"date":"","count":2159,"signal":"Sleep disorder due to a general medical condition","source":"DrugCentral FAERS","actionTaken":"Reported 2,159 times (LLR=3973)"},{"llr":3602.892,"date":"","count":2537,"signal":"Obstructive airways disorder","source":"DrugCentral FAERS","actionTaken":"Reported 2,537 times (LLR=3603)"},{"llr":3176.544,"date":"","count":2712,"signal":"Full blood count abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 2,712 times (LLR=3177)"},{"llr":2884.669,"date":"","count":8142,"signal":"Cough","source":"DrugCentral FAERS","actionTaken":"Reported 8,142 times (LLR=2885)"},{"llr":2685.069,"date":"","count":2534,"signal":"Product quality issue","source":"DrugCentral FAERS","actionTaken":"Reported 2,534 times (LLR=2685)"},{"llr":2261.574,"date":"","count":843,"signal":"Poor quality device used","source":"DrugCentral FAERS","actionTaken":"Reported 843 times (LLR=2262)"},{"llr":2137.031,"date":"","count":3049,"signal":"Productive cough","source":"DrugCentral FAERS","actionTaken":"Reported 3,049 times (LLR=2137)"},{"llr":2105.937,"date":"","count":3109,"signal":"Chronic obstructive pulmonary disease","source":"DrugCentral FAERS","actionTaken":"Reported 3,109 times (LLR=2106)"},{"llr":1812.139,"date":"","count":3919,"signal":"Therapeutic product effect incomplete","source":"DrugCentral FAERS","actionTaken":"Reported 3,919 times (LLR=1812)"},{"llr":1598.128,"date":"","count":553,"signal":"Device delivery system issue","source":"DrugCentral FAERS","actionTaken":"Reported 553 times (LLR=1598)"},{"llr":1561.635,"date":"","count":3446,"signal":"Chest discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 3,446 times (LLR=1562)"},{"llr":1510.445,"date":"","count":3043,"signal":"Loss of personal independence in daily activities","source":"DrugCentral FAERS","actionTaken":"Reported 3,043 times (LLR=1510)"}],"commonSideEffects":[{"effect":"Upper Respiratory Tract Infection","drugRate":"21%","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Nervousness","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Inhalation Site Sensation","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Allergic Reaction/Symptoms","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Respiratory Disorder (unspecified)","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Back Pain","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Inhalation Taste Sensation","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Urinary Tract Infection","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic myocardial ischemia","Conduction disorder of the heart","Congenital long QT syndrome","Diabetes mellitus","Hypertensive disorder","Hyperthyroidism","Hypokalemia","Ketoacidosis","Metabolic acidosis","Myocardial ischemia","Ocular hypertension","Paradoxical bronchospasm","Prolonged QT interval","Retention of urine","Seizure disorder"],"specialPopulations":{"Pregnancy":"There are no randomized clinical studies of use of albuterol during pregnancy. Available data from published epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate risk of major birth defects or miscarriage. There are clinical considerations with use of albuterol in pregnant women. Albuterol sulfate has been shown to be teratogenic in mice. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown.","Geriatric use":"PROVENTIL HFA Inhalation Aerosol has not been studied in geriatric population. As with other beta2-agonists, special caution should be observed when using PROVENTIL HFA Inhalation Aerosol in elderly patients who have concomitant cardiovascular disease that could be adversely affected by this class of drug.","Paediatric use":"The safety and effectiveness of PROVENTIL HFA Inhalation Aerosol in pediatric patients below the age of 4 years have not been established."},"seriousAdverseEvents":[{"effect":"Urticaria","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Rash","drugRate":"","severity":"serious"},{"effect":"Bronchospasm","drugRate":"","severity":"serious"},{"effect":"Oropharyngeal Edema","drugRate":"","severity":"serious"},{"effect":"Hypertension","drugRate":"","severity":"serious"},{"effect":"Angina","drugRate":"","severity":"serious"},{"effect":"Metabolic Acidosis","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Inhaled Ventoline (Evohaler) 0,1 mg/dos","Salbutrim","bronchodilator","Ventoline","Salbutamol -100µg+300µg"],"company":"Merck & Co.","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2041-02-22","territory":"US","patentNumber":"11266796"},{"source":"FDA Orange Book via DrugCentral","expires":"2040-07-06","territory":"US","patentNumber":"11173259"},{"source":"FDA Orange Book via DrugCentral","expires":"2040-06-19","territory":"US","patentNumber":"11464923"},{"source":"FDA Orange Book via DrugCentral","expires":"2040-05-24","territory":"US","patentNumber":"11439777"},{"source":"FDA Orange Book via DrugCentral","expires":"2039-09-26","territory":"US","patentNumber":"11344685"},{"source":"FDA Orange Book via DrugCentral","expires":"2038-12-18","territory":"US","patentNumber":"11000653"},{"source":"FDA Orange Book via DrugCentral","expires":"2038-09-24","territory":"US","patentNumber":"11357935"},{"source":"FDA Orange Book via DrugCentral","expires":"2038-02-10","territory":"US","patentNumber":"11351317"},{"source":"FDA Orange Book via DrugCentral","expires":"2036-08-16","territory":"US","patentNumber":"10569034"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-12-14","territory":"US","patentNumber":"10918816"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-08-28","territory":"US","patentNumber":"9782550"},{"source":"FDA Orange Book via DrugCentral","expires":"2035-08-28","territory":"US","patentNumber":"9782551"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-01-13","territory":"US","patentNumber":"8978966"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-01-01","territory":"US","patentNumber":"10561808"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-06-28","territory":"US","patentNumber":"9216260"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10022509"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10022510"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10086156"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10124131"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"10695512"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"11395889"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"9463289"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"9731087"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-05-18","territory":"US","patentNumber":"9808587"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-10-16","territory":"US","patentNumber":"8733341"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-05-28","territory":"US","patentNumber":"9415009"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-09-07","territory":"US","patentNumber":"8132712"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-03-26","territory":"US","patentNumber":"8651103"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-03-13","territory":"US","patentNumber":"7837235"},{"source":"FDA Orange Book via DrugCentral","expires":"2027-03-31","territory":"US","patentNumber":"9027967"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-10-10","territory":"US","patentNumber":"7396341"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-26","territory":"US","patentNumber":"7500444*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-02-26","territory":"US","patentNumber":"7500444"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-26","territory":"US","patentNumber":"7896264"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-19","territory":"US","patentNumber":"10765820"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-19","territory":"US","patentNumber":"9463288"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-08-26","territory":"US","patentNumber":"7284474"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-12-19","territory":"US","patentNumber":"7832351*PED"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-09-12","territory":"US","patentNumber":"7105152"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-06-19","territory":"US","patentNumber":"7832351"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-05-06","territory":"US","patentNumber":"7540282"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=salbutamol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:27.665812+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:27.665712+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:43:33.416798+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=salbutamol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:43:33.763894+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Beta-2 adrenergic receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:34.812386+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL714/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:34.481223+00:00"}},"allNames":"proventil","offLabel":[],"synonyms":["salbutamol","albuterol","sabumol","dl-Albuterol","dl-Salbutamol","albuterol sulfate"],"timeline":[{"date":"1981-05-01","type":"positive","source":"DrugCentral","milestone":"FDA approval (Schering)"}],"aiSummary":"Proventil (salbutamol) is a small molecule beta2-Adrenergic Agonist developed by SCHERING, targeting the beta-2 adrenergic receptor. It is used to treat various respiratory conditions, including acute asthma exacerbations, bronchospasm, and chronic obstructive pulmonary disease. Proventil was FDA-approved in 1981 and is still owned by SCHERING. Key safety considerations include potential cardiovascular effects and interactions with other medications. Proventil is used to relax airway muscles and improve breathing.","approvals":[{"date":"1981-05-01","orphan":false,"company":"SCHERING","regulator":"FDA"}],"brandName":"Proventil","ecosystem":[{"indication":"Acute exacerbation of asthma","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"norepinephrine","slug":"norepinephrine","company":"Hospira"}],"globalPrevalence":262000000},{"indication":"Bronchospasm","otherDrugs":[{"name":"diprophylline","slug":"diprophylline","company":""},{"name":"ephedrine","slug":"ephedrine","company":""},{"name":"ipratropium","slug":"ipratropium","company":""},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"}],"globalPrevalence":null},{"indication":"Bronchospasm Prevention","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"orciprenaline","slug":"orciprenaline","company":""}],"globalPrevalence":null},{"indication":"Chronic Obstructive Pulmonary Disease with Bronchospasms","otherDrugs":[{"name":"ipratropium","slug":"ipratropium","company":""},{"name":"terbutaline","slug":"terbutaline","company":""},{"name":"theophylline","slug":"theophylline","company":"Gd Searle Llc"},{"name":"tiotropium bromide","slug":"tiotropium-bromide","company":"Boehringer Ingelheim"}],"globalPrevalence":392000000},{"indication":"Exercise-Induced Bronchospasm Prevention","otherDrugs":[{"name":"formoterol","slug":"formoterol","company":"Novartis"},{"name":"montelukast","slug":"montelukast","company":"Merck"},{"name":"salmeterol","slug":"salmeterol","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Beta-2 adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor"},{"gene":"ADRB1","source":"DrugCentral","target":"Beta-1 adrenergic receptor","protein":"Beta-1 adrenergic receptor"}],"moaClass":"Adrenergic beta2-Agonists","modality":"Small Molecule","drugClass":"beta2-Adrenergic Agonist","explanation":"","oneSentence":"","technicalDetail":"Proventil (salbutamol) is a selective beta-2 adrenergic receptor agonist that activates the receptor, leading to an increase in intracellular cyclic AMP (cAMP) levels, which in turn causes relaxation of airway smooth muscle cells and bronchodilation."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-05-01, SCHERING)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/105","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=salbutamol","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=salbutamol","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:38:02.052998","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:36.098538+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"terbutaline","drugSlug":"terbutaline","fdaApproval":"1974-03-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isoetarine","drugSlug":"isoetarine","fdaApproval":"1979-10-23","relationship":"same-class"},{"drugName":"pirbuterol","drugSlug":"pirbuterol","fdaApproval":"1986-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"salmeterol","drugSlug":"salmeterol","fdaApproval":"1994-02-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"formoterol","drugSlug":"formoterol","fdaApproval":"2001-02-16","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clenbuterol","drugSlug":"clenbuterol","fdaApproval":"","relationship":"same-class"},{"drugName":"bitolterol","drugSlug":"bitolterol","fdaApproval":"1984-12-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"indacaterol","drugSlug":"indacaterol","fdaApproval":"2011-07-01","patentExpiry":"Oct 11, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"olodaterol","drugSlug":"olodaterol","fdaApproval":"2014-07-31","patentExpiry":"Jan 19, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"salbutamol","indications":{"approved":[{"name":"Acute exacerbation of asthma","source":"DrugCentral","snomedId":708038006,"regulator":"FDA","eligibility":"Adults and children 6 years of age and older","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Bronchospasm","source":"DrugCentral","snomedId":4386001,"regulator":"FDA","eligibility":"Adults and children 6 years of age and older"},{"name":"Bronchospasm Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children 6 years of age and older"},{"name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children 6 years of age and older","usPrevalence":16000000,"globalPrevalence":392000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Exercise-Induced Bronchospasm Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children 6 years of age and older"}],"offLabel":[{"name":"Chronic obstructive lung disease","source":"DrugCentral","drugName":"salbutamol"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"terbutaline","brandName":"terbutaline","genericName":"terbutaline","approvalYear":"1974","relationship":"same-class"},{"drugId":"isoetarine","brandName":"isoetarine","genericName":"isoetarine","approvalYear":"1979","relationship":"same-class"},{"drugId":"pirbuterol","brandName":"pirbuterol","genericName":"pirbuterol","approvalYear":"1986","relationship":"same-class"},{"drugId":"salmeterol","brandName":"salmeterol","genericName":"salmeterol","approvalYear":"1994","relationship":"same-class"},{"drugId":"formoterol","brandName":"formoterol","genericName":"formoterol","approvalYear":"2001","relationship":"same-class"},{"drugId":"clenbuterol","brandName":"clenbuterol","genericName":"clenbuterol","approvalYear":"","relationship":"same-class"},{"drugId":"bitolterol","brandName":"bitolterol","genericName":"bitolterol","approvalYear":"1984","relationship":"same-class"},{"drugId":"indacaterol","brandName":"indacaterol","genericName":"indacaterol","approvalYear":"2011","relationship":"same-class"},{"drugId":"olodaterol","brandName":"olodaterol","genericName":"olodaterol","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06379607","phase":"NA","title":"High Flow Nasal Cannula Rates in Pediatric Asthma","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2025-01-15","conditions":["Pediatric Asthma"],"enrollment":0,"completionDate":"2026-09-30"},{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":["Asthma"],"enrollment":2700,"completionDate":"2026-10-31"},{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":["Asthma"],"enrollment":1147,"completionDate":"2027-10-15"},{"nctId":"NCT01799538","phase":"PHASE1,PHASE2","title":"Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-06-10","conditions":["Lymphangioleiomyomatosis"],"enrollment":100,"completionDate":"2027-11-01"},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":["Asthma"],"enrollment":724,"completionDate":"2026-05-31"},{"nctId":"NCT03890666","phase":"PHASE4","title":"A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-10-26","conditions":["Asthma"],"enrollment":333,"completionDate":"2021-10-04"},{"nctId":"NCT06471257","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":["Asthma"],"enrollment":790,"completionDate":"2026-10-30"},{"nctId":"NCT07037511","phase":"NA","title":"Effects of Salbutamol in Athletes and Implications for Screening and Sports","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-10-30","conditions":["Asthma","Healthy","Effect of Drug"],"enrollment":64,"completionDate":"2030-12-31"},{"nctId":"NCT07141277","phase":"","title":"GRANITE: Airsupra Effectiveness in the Real World","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-09","conditions":["Asthma"],"enrollment":4000,"completionDate":"2026-06-30"},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":["Severe Asthma"],"enrollment":326,"completionDate":"2027-06-25"},{"nctId":"NCT03822637","phase":"PHASE4","title":"The Effect of NAC on Lung Function and CT Mucus Score","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2019-02-20","conditions":["Asthma"],"enrollment":4,"completionDate":"2025-02-21"},{"nctId":"NCT06307665","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-20","conditions":["Asthma"],"enrollment":440,"completionDate":"2027-10-13"},{"nctId":"NCT01931696","phase":"NA","title":"Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-08","conditions":["Asthma"],"enrollment":200,"completionDate":"2015-07"},{"nctId":"NCT06261957","phase":"PHASE3","title":"A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-31","conditions":["Asthma"],"enrollment":477,"completionDate":"2025-09-02"},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":["Hypertension (HTN)","Diarrhea","Pneumonia","Malaria Fever","COPD","Asthma (Diagnosis)","Diarrhea Chronic"],"enrollment":72564,"completionDate":"2023-08-31"},{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":["Mild Asthma"],"enrollment":101,"completionDate":"2026-02-24"},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":["Asthma"],"enrollment":422,"completionDate":"2026-03-03"},{"nctId":"NCT00585039","phase":"PHASE4","title":"Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2005-09","conditions":["Asthma"],"enrollment":101,"completionDate":"2009-03"},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":["Asthma"],"enrollment":304,"completionDate":"2029-12-24"},{"nctId":"NCT07378605","phase":"NA","title":"Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery","status":"NOT_YET_RECRUITING","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2026-01-01","conditions":["Bariatric Surgery"],"enrollment":66,"completionDate":"2026-03-15"},{"nctId":"NCT03900494","phase":"NA","title":"Comparing the Efficacy of Two Valved Holding Chambers in Acute Wheezing","status":"COMPLETED","sponsor":"Tampere University","startDate":"2019-04-17","conditions":["Bronchitis Obstructive","Bronchiolitis; Obstruction","Bronchospasm; Bronchitis"],"enrollment":80,"completionDate":"2025-05-23"},{"nctId":"NCT05555290","phase":"PHASE3","title":"PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-28","conditions":["Asthma"],"enrollment":190,"completionDate":"2024-11-18"},{"nctId":"NCT01229384","phase":"NA","title":"Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2011-10","conditions":["Bronchiolitis"],"enrollment":0,"completionDate":"2013-03"},{"nctId":"NCT06099275","phase":"","title":"Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography","status":"SUSPENDED","sponsor":"Brigham and Women's Hospital","startDate":"2026-10-25","conditions":["Preeclampsia"],"enrollment":80,"completionDate":"2027-10-11"},{"nctId":"NCT07350421","phase":"NA","title":"The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN)","status":"NOT_YET_RECRUITING","sponsor":"Tishreen University","startDate":"2026-01-01","conditions":["TTN"],"enrollment":1,"completionDate":"2028-03-01"},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":["Asthma"],"enrollment":1038,"completionDate":"2028-12-31"},{"nctId":"NCT06433908","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-06-04","conditions":["Asthma","Healthy Participants"],"enrollment":60,"completionDate":"2024-10-22"},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":["Asthma"],"enrollment":1507,"completionDate":"2026-04-29"},{"nctId":"NCT01958814","phase":"PHASE2","title":"Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2012-02","conditions":["Chronic Respiratory Failure"],"enrollment":43,"completionDate":"2015-07"},{"nctId":"NCT02812979","phase":"NA","title":"Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-06","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":25,"completionDate":"2018-04-27"},{"nctId":"NCT06036823","phase":"PHASE4","title":"5 Versus 10 Units of Insulin in Hyperkalemia Management","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2023-10-01","conditions":["Hyperkalemia","Potassium Imbalance","Electrolyte Imbalance","Electrolyte Disturbance"],"enrollment":384,"completionDate":"2025-09-30"},{"nctId":"NCT06785272","phase":"PHASE3","title":"Magnesium Trial in Acute Asthma in Emergency Department","status":"RECRUITING","sponsor":"Suzanne Schuh","startDate":"2025-10-08","conditions":["Asthma"],"enrollment":192,"completionDate":"2027-10"},{"nctId":"NCT03952286","phase":"PHASE4","title":"ED-Initiated School-based Asthma Medication Supervision","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2019-08-01","conditions":["Asthma","Asthma in Children"],"enrollment":13,"completionDate":"2021-01-01"},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":["Healthy"],"enrollment":81,"completionDate":"2025-09-25"},{"nctId":"NCT05527704","phase":"PHASE3","title":"the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2021-12-31","conditions":["TTN","Respiratory Failure","PPHN"],"enrollment":608,"completionDate":"2026-09-30"},{"nctId":"NCT01851642","phase":"","title":"Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs","status":"RECRUITING","sponsor":"University of Florida","startDate":"2007-08-09","conditions":["Alpha-1 Antitrypsin Deficiency","AAT Deficiency","AATD","Cystic Fibrosis (CF)"],"enrollment":220,"completionDate":"2033-07-20"},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":["Asthma","Asthma Attack","Asthma Exacerbations"],"enrollment":3200,"completionDate":"2029-11-15"},{"nctId":"NCT06433921","phase":"PHASE1","title":"A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-14","conditions":["Asthma","Mild Asthma"],"enrollment":84,"completionDate":"2026-11-06"},{"nctId":"NCT06512064","phase":"NA","title":"Acoustic Waveform Respiratory Evaluation","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-07-23","conditions":["Asthma","COPD","Cystic Fibrosis","Ciliary Motility Disorders","Bronchiectasis","Airway Malacia","Healthy Control"],"enrollment":800,"completionDate":"2029-04"},{"nctId":"NCT06876064","phase":"","title":"National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-10","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT06040268","phase":"PHASE1,PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":["Altitude Edema"],"enrollment":60,"completionDate":"2026-12-15"},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":["Stem Cell Transplant Complications","Respiratory Disease","Bronchiolitis Obliterans"],"enrollment":35,"completionDate":"2023-09-27"},{"nctId":"NCT05366764","phase":"PHASE1","title":"First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-06-08","conditions":["Asthma"],"enrollment":36,"completionDate":"2023-02-24"},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":["Primary Ciliary Dyskinesia"],"enrollment":27,"completionDate":"2024-07-22"},{"nctId":"NCT06644924","phase":"PHASE2","title":"A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-02-10","conditions":["Asthma"],"enrollment":118,"completionDate":"2025-06-04"},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":["Asthma"],"enrollment":72,"completionDate":"2023-07-20"},{"nctId":"NCT06245551","phase":"PHASE3","title":"A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-22","conditions":["Asthma, Exercise-Induced"],"enrollment":64,"completionDate":"2024-06-29"},{"nctId":"NCT06514157","phase":"PHASE1","title":"Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-19","conditions":["Healthy Volunteer"],"enrollment":14,"completionDate":"2024-09-09"},{"nctId":"NCT05848115","phase":"NA","title":"BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2023-06-23","conditions":["Asthma in Children"],"enrollment":67,"completionDate":"2025-07-07"},{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":48,"completionDate":"2025-01-23"},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":["Asthma"],"enrollment":30,"completionDate":"2024-10-07"},{"nctId":"NCT07118644","phase":"PHASE3","title":"Microbiote's Evolution After Use of Nitrous Oxide on Pediatric Patient Needing Airway Samples","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-09-01","conditions":["Respiratory Ilness","Children"],"enrollment":40,"completionDate":"2027-09-06"},{"nctId":"NCT06097507","phase":"NA","title":"Patient Perspective on Climate Impact of Inhalers","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-07","conditions":["Asthma"],"enrollment":54,"completionDate":"2024-06-01"},{"nctId":"NCT07112456","phase":"PHASE2","title":"Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2026-09-01","conditions":["Asthma Acute","Asthma Attack","Asthma Exacerbations"],"enrollment":100,"completionDate":"2029-08-31"},{"nctId":"NCT03556683","phase":"NA","title":"Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-10-01","conditions":["Moderate to Severe Asthma"],"enrollment":24,"completionDate":"2024-06-06"},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":["Asthma"],"enrollment":2516,"completionDate":"2024-08-22"},{"nctId":"NCT06152653","phase":"PHASE4","title":"The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-04-09","conditions":["Asthma","COPD"],"enrollment":40,"completionDate":"2027-04"},{"nctId":"NCT05457868","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":124117,"completionDate":"2023-12-31"},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":["Bronchial Asthma"],"enrollment":120,"completionDate":"2024-11-29"},{"nctId":"NCT04997304","phase":"PHASE4","title":"Teva Asthma Predictive Analytics Study","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-07-09","conditions":["Asthma"],"enrollment":100,"completionDate":"2023-12-14"},{"nctId":"NCT05914285","phase":"NA","title":"Assessment of Salbutamol Effect on Arterial Oxygenation in COPD Patients During One-lung Ventilation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-25","conditions":["One-lung Ventilation","Chronic Obstructive Pulmonary Disease"],"enrollment":90,"completionDate":"2025-07-21"},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":["Status Asthmaticus"],"enrollment":90,"completionDate":"2026-06-30"},{"nctId":"NCT05099107","phase":"NA","title":"Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-10-25","conditions":["Congenital Myopathy","Neuromuscular Diseases","Musculoskeletal Diseases","Nemaline Myopathy","Centronuclear Myopathy","Myosin Storage Myopathy"],"enrollment":18,"completionDate":"2025-03-17"},{"nctId":"NCT04821869","phase":"","title":"ProAir Digihaler in COPD Disease Management: A Real World Study","status":"COMPLETED","sponsor":"Pulmonary Research Institute of Southeast Michigan","startDate":"2021-05-10","conditions":["COPD","COPD Exacerbation Acute"],"enrollment":27,"completionDate":"2022-06-21"},{"nctId":"NCT05108831","phase":"NA","title":"Dynamic CDSA to Manage Sick Children in Rwanda","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2021-12-01","conditions":["Child Health"],"enrollment":85212,"completionDate":"2024-12-31"},{"nctId":"NCT05667727","phase":"PHASE4","title":"The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2023-10-15","conditions":["Shortness of Breath","Asthma in Children","Epinephrine Causing Adverse Effects in Therapeutic Use","Salbutamol Adverse Reaction"],"enrollment":30,"completionDate":"2025-06-01"},{"nctId":"NCT05035862","phase":"PHASE1","title":"Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-03-16","conditions":["Asthma"],"enrollment":1,"completionDate":"2022-12-16"},{"nctId":"NCT05653024","phase":"PHASE3","title":"INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions","status":"TERMINATED","sponsor":"Philippe Bégin","startDate":"2023-07-01","conditions":["IgE-mediated Abdominal Pain"],"enrollment":24,"completionDate":"2025-05-05"},{"nctId":"NCT06980727","phase":"PHASE3","title":"Comparative Efficacy of IV Dexamethasone vs. Nebulized Salbutamol for Renal Colic Pain in the ED","status":"NOT_YET_RECRUITING","sponsor":"University of Monastir","startDate":"2025-06-01","conditions":["Renal Colic"],"enrollment":300,"completionDate":"2028-03-01"},{"nctId":"NCT05009758","phase":"NA","title":"Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2021-09-01","conditions":["Asthma","Chronic Rhinosinusitis With Nasal Polyps","Chronic Rhinosinusitis (Diagnosis)","Nasal Polyps"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT05786950","phase":"NA","title":"Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-01-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":44,"completionDate":"2024-09-01"},{"nctId":"NCT06946264","phase":"PHASE3","title":"Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features","status":"RECRUITING","sponsor":"Nemours Children's Clinic","startDate":"2022-07-08","conditions":["Bronchiolitis","Bronchodilator Agents"],"enrollment":400,"completionDate":"2030-12-31"},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":["Asthma","Bronchial Diseases","Respiratory Tract Infections","Lung Diseases, Obstructive","Lung Diseases","Respiratory Hypersensitivity","Immune System Diseases"],"enrollment":103,"completionDate":"2024-12-31"},{"nctId":"NCT05987371","phase":"PHASE2","title":"A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-23","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":75,"completionDate":"2024-04-23"},{"nctId":"NCT06921291","phase":"PHASE1","title":"Role of Salbutamol in the Management of Transient Tachypnea of the New Born","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2024-08-01","conditions":["TTN"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT06654986","phase":"NA","title":"Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":["Healthy"],"enrollment":36,"completionDate":"2026-12-18"},{"nctId":"NCT06655012","phase":"NA","title":"Salmeterol Effect on Exercise Performance","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":["Healthy"],"enrollment":36,"completionDate":"2026-12-31"},{"nctId":"NCT06918418","phase":"PHASE4","title":"A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children","status":"COMPLETED","sponsor":"Children's Hospital and Institute of Child Health, Multan","startDate":"2024-01-01","conditions":["Asthma Exacerbation","Children"],"enrollment":60,"completionDate":"2024-07-15"},{"nctId":"NCT06909903","phase":"NA","title":"Cell Content of Sputum Induced by Hypertonic Saline in Adolescents With Cystic Fibrosis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-07-20","conditions":["Cystic Fibrosis"],"enrollment":17,"completionDate":"2021-10-10"},{"nctId":"NCT01202097","phase":"PHASE3","title":"A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":["Asthma"],"enrollment":334,"completionDate":"2012-05"},{"nctId":"NCT03522831","phase":"NA","title":"CF Bronchodilation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2018-05-01","conditions":["Lung Diseases","Cystic Fibrosis"],"enrollment":20,"completionDate":"2027-12-31"},{"nctId":"NCT02797275","phase":"PHASE4","title":"Secondhand Smoke Respiratory Health Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2016-06-06","conditions":["Secondhand Smoke","Air Trapping","Tobacco","Airflow Limitation","Hyperinflation","Obstructive Lung Disease"],"enrollment":107,"completionDate":"2025-12-31"},{"nctId":"NCT06884228","phase":"NA","title":"Effects of Vibrating Mesh Nebulisation in Patients With COPD During Non-invasive Ventilation (VMN-NIV)","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-03-21","conditions":["COPD (Chronic Obstructive Pulmonary Disease)","Non-invasive Ventilation"],"enrollment":12,"completionDate":"2026-05-01"},{"nctId":"NCT03305549","phase":"NA","title":"Recovery After Dialysis-Requiring Acute Kidney Injury","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-09-29","conditions":["Acute Kidney Injury"],"enrollment":16,"completionDate":"2019-11-13"},{"nctId":"NCT05087693","phase":"PHASE4","title":"Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":["Asthma and/or Exercise Induced Bronchoconstriction","Ozone Air Pollution"],"enrollment":18,"completionDate":"2023-08-31"},{"nctId":"NCT06201156","phase":"NA","title":"Comparison of Nebulizers vs Metered-Dose Inhalers With Spacer Device For Treatment Of Childhood Wheeze","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-12-10","conditions":["Childhood Asthma With Acute Exacerbation"],"enrollment":160,"completionDate":"2024-03-30"},{"nctId":"NCT06834581","phase":"NA","title":"Effects of Vibrating Mesh Nebulisation in Patients on Long-term Tracheostomy Ventilation: a Pilot Randomised Crossover Trial","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-03-01","conditions":["Long-term Tracheostomy Ventilated Patients"],"enrollment":12,"completionDate":"2026-05-01"},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":["Mild Asthma"],"enrollment":148,"completionDate":"2025-06"},{"nctId":"NCT05724745","phase":"NA","title":"Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)","status":"RECRUITING","sponsor":"Commissariat A L'energie Atomique","startDate":"2023-05-26","conditions":["Asthma","COPD","BOS"],"enrollment":240,"completionDate":"2028-05"},{"nctId":"NCT06093152","phase":"","title":"Video Assisted Study of Salbutamol Response in Viral Wheezing","status":"RECRUITING","sponsor":"University of Oulu","startDate":"2023-10-23","conditions":["Wheezing"],"enrollment":50,"completionDate":"2026-12"},{"nctId":"NCT06825013","phase":"PHASE4","title":"Bronchodilators and Lung Mechanics During Exercise in COPD","status":"RECRUITING","sponsor":"Dr. J. Alberto Neder","startDate":"2024-11-10","conditions":["COPD"],"enrollment":25,"completionDate":"2027-01"},{"nctId":"NCT06816342","phase":"PHASE4","title":"Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-11-01","conditions":["Asthmatic Patients","MDI","Aerosol Generating Procedure"],"enrollment":120,"completionDate":"2025-02-10"},{"nctId":"NCT06815679","phase":"PHASE2,PHASE3","title":"Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC","status":"NOT_YET_RECRUITING","sponsor":"Università degli Studi di Ferrara","startDate":"2025-03-01","conditions":["Acute Respiratory Failure","Pneumonia"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":["Airway Inflammation","Asthma"],"enrollment":42,"completionDate":"2022-12-16"},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":["Asthma","Severe Eosinophilic Asthma"],"enrollment":170,"completionDate":"2023-01-31"},{"nctId":"NCT06754631","phase":"NA","title":"Efficacy and Safety of Continuous Versus Intermittent Nebulization of Salbutamol in Acute Severe Asthma in Children Under 12 Years of Age","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2024-04-01","conditions":["Asthma in Children"],"enrollment":120,"completionDate":"2024-09-30"},{"nctId":"NCT05144763","phase":"NA","title":"Dynamic CDSA to Manage Sick Children in Tanzania","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2021-12-01","conditions":["Child Health"],"enrollment":92331,"completionDate":"2024-09-30"},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":["Asthma"],"enrollment":100,"completionDate":"2023-10-28"},{"nctId":"NCT05977699","phase":"PHASE4","title":"Reversibility of Methacholine Induced Bronchoconstriction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2024-01-12","conditions":["Asthma"],"enrollment":20,"completionDate":"2024-12-30"},{"nctId":"NCT03455959","phase":"NA","title":"Lung-Resident Memory Th2 Cells in Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew D. Luster, M.D.,Ph.D.","startDate":"2019-05-23","conditions":["Asthma, Allergic"],"enrollment":37,"completionDate":"2025-12-15"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Respiratory (Inhalation), Oral","formulation":"Aerosol","formulations":[{"form":"AEROSOL, METERED","route":"ORAL","productName":"Albuterol"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"ALBUTEROL SULFATE"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Albuterol Sulfate"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Albuterol sulfate"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"albuterol sulfate"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"ALBUTEROL SULFATE"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"ALBUTEROL SULFATEHFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Albuterol Sulfate\nHFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Albuterol SulfateHFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"PROAIR\n                                    HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"PROAIRHFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"PROAIRHFA\n                     HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"Proventil HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"VENTOLIN\n                                    HFA"},{"form":"AEROSOL, METERED","route":"RESPIRATORY (INHALATION)","productName":"VENTOLIN HFA"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147099","MMSL":"3007","NDDF":"001814","UNII":"QF8SVZ843E","VUID":"4018796","CHEBI":"CHEBI:2549","VANDF":"4018796","INN_ID":"2585","RXNORM":"142153","UMLSCUI":"C0001927","chemblId":"CHEMBL714","ChEMBL_ID":"CHEMBL714","KEGG_DRUG":"D02147","DRUGBANK_ID":"DB01001","PDB_CHEM_ID":" 68H","PUBCHEM_CID":"2083","SNOMEDCT_US":"372897005","IUPHAR_LIGAND_ID":"558","SECONDARY_CAS_RN":"51022-70-9","MESH_DESCRIPTOR_UI":"D000420"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1981-","companyName":"Schering","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.4 hours","clearance":"7.8 mL/min/kg","bioavailability":"44%","fractionUnbound":"0.92%","volumeOfDistribution":"1.9 L/kg"},"publicationCount":8350,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"R03AC02","allCodes":["R03AC02","R03AK04","R03AK13","R03AL02","R03CC02"]},"biosimilarFilings":[],"originalDeveloper":"Schering","recentPublications":[],"combinationProducts":[{"brandName":"Combivent Respimat","ingredients":"ipratropium + salbutamol"},{"brandName":"Ipratropium Bromide and Albuterol Sulfate","ingredients":"ipratropium + salbutamol"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Merck & Co.","companyId":"merck","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1981-05-01T00:00:00.000Z","mah":"SCHERING","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7540282","territory":"US","patent_type":null,"expiry_date":"2023-05-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7832351","territory":"US","patent_type":null,"expiry_date":"2023-06-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7105152","territory":"US","patent_type":null,"expiry_date":"2023-09-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7832351*PED","territory":"US","patent_type":null,"expiry_date":"2023-12-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7284474","territory":"US","patent_type":null,"expiry_date":"2024-08-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9463288","territory":"US","patent_type":null,"expiry_date":"2025-05-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10765820","territory":"US","patent_type":null,"expiry_date":"2025-05-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7896264","territory":"US","patent_type":null,"expiry_date":"2025-05-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7500444","territory":"US","patent_type":null,"expiry_date":"2026-02-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7500444*PED","territory":"US","patent_type":null,"expiry_date":"2026-08-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7396341","territory":"US","patent_type":null,"expiry_date":"2026-10-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9027967","territory":"US","patent_type":null,"expiry_date":"2027-03-31T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7837235","territory":"US","patent_type":null,"expiry_date":"2028-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8651103","territory":"US","patent_type":null,"expiry_date":"2028-03-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8132712","territory":"US","patent_type":null,"expiry_date":"2028-09-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9415009","territory":"US","patent_type":null,"expiry_date":"2030-05-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8733341","territory":"US","patent_type":null,"expiry_date":"2030-10-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9731087","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9463289","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11395889","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10695512","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10124131","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10086156","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022510","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022509","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9808587","territory":"US","patent_type":null,"expiry_date":"2031-05-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9216260","territory":"US","patent_type":null,"expiry_date":"2031-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10561808","territory":"US","patent_type":null,"expiry_date":"2032-01-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8978966","territory":"US","patent_type":null,"expiry_date":"2032-01-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9782551","territory":"US","patent_type":null,"expiry_date":"2035-08-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9782550","territory":"US","patent_type":null,"expiry_date":"2035-08-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10918816","territory":"US","patent_type":null,"expiry_date":"2035-12-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10569034","territory":"US","patent_type":null,"expiry_date":"2036-08-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11351317","territory":"US","patent_type":null,"expiry_date":"2038-02-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11357935","territory":"US","patent_type":null,"expiry_date":"2038-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11000653","territory":"US","patent_type":null,"expiry_date":"2038-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11344685","territory":"US","patent_type":null,"expiry_date":"2039-09-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11439777","territory":"US","patent_type":null,"expiry_date":"2040-05-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11464923","territory":"US","patent_type":null,"expiry_date":"2040-06-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11173259","territory":"US","patent_type":null,"expiry_date":"2040-07-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11266796","territory":"US","patent_type":null,"expiry_date":"2041-02-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":5,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:36.098538+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}